Education
About Us
Working with TipRanks
Follow Us
BrightPath Biotherapeutics Co.Ltd. (JP:4594)
:4594
RESEARCH TOOLSreports
Total Valuation
BrightPath Biotherapeutics Co.Ltd. has a market cap or net worth of ¥3.74B. The enterprise value is ¥8.73B.
Market Cap¥3.74B
Enterprise Value¥8.73B
Share Statistics
BrightPath Biotherapeutics Co.Ltd. has 93,441,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding93,441,300
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
BrightPath Biotherapeutics Co.Ltd.’s return on equity (ROE) is -1.24 and return on invested capital (ROIC) is -114.68%.
Return on Equity (ROE)-1.24
Return on Assets (ROA)-1.03
Return on Invested Capital (ROIC)-114.68%
Return on Capital Employed (ROCE)-1.17
Revenue Per Employee26.98K
Profits Per Employee-27.41M
Employee Count42
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of BrightPath Biotherapeutics Co.Ltd. is -3.12. BrightPath Biotherapeutics Co.Ltd.’s PEG ratio is 0.54.
PE Ratio-3.12
PS Ratio0.00
PB Ratio6.55
Price to Fair Value3.88
Price to FCF-8.51
Price to Operating Cash Flow-8.52
PEG Ratio0.54
Income Statement
In the last 12 months, BrightPath Biotherapeutics Co.Ltd. had revenue of 1.13M and earned -1.15B in profits. Earnings per share was -14.12.
Revenue1.13M
Gross Profit1.10M
Operating Income-1.16B
Pretax Income-1.15B
Net Income-1.15B
EBITDA-1.15B
Earnings Per Share (EPS)-14.12
Cash Flow
In the last 12 months, operating cash flow was 8.98M and capital expenditures 0.00, giving a free cash flow of 8.98M billion.
Operating Cash Flow8.98M
Free Cash Flow8.98M
Free Cash Flow per Share0.10
Dividends & Yields
BrightPath Biotherapeutics Co.Ltd. pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.19
52-Week Price Change-34.38%
50-Day Moving Average39.50
200-Day Moving Average45.75
Relative Strength Index (RSI)58.27
Average Volume (3m)297.61K
Important Dates
BrightPath Biotherapeutics Co.Ltd. upcoming earnings date is Aug 8, 2025, TBA Not Confirmed.
Last Earnings DateMay 9, 2025
Next Earnings DateAug 8, 2025
Ex-Dividend Date―
Financial Position
BrightPath Biotherapeutics Co.Ltd. as a current ratio of 8.14, with Debt / Equity ratio of 0.00%
Current Ratio8.14
Quick Ratio8.14
Debt to Market Cap<0.01
Net Debt to EBITDA0.68
Interest Coverage Ratio0.00
Taxes
In the past 12 months, BrightPath Biotherapeutics Co.Ltd. has paid 1.90M in taxes.
Income Tax1.90M
Effective Tax Rate>-0.01
Enterprise Valuation
BrightPath Biotherapeutics Co.Ltd. EV to EBITDA ratio is -2.44, with an EV/FCF ratio of -2.24.
EV to Sales2.47K
EV to EBITDA-2.44
EV to Free Cash Flow-2.24
EV to Operating Cash Flow-2.24
Balance Sheet
BrightPath Biotherapeutics Co.Ltd. has ¥1.30B in cash and marketable securities with ¥500.00M in debt, giving a net cash position of -¥796.94M billion.
Cash & Marketable Securities¥1.30B
Total Debt¥500.00M
Net Cash-¥796.94M
Net Cash Per Share-¥8.53
Tangible Book Value Per Share¥11.35
Margins
Gross margin is 64.11%, with operating margin of -102464.08%, and net profit margin of -101601.85%.
Gross Margin64.11%
Operating Margin-102464.08%
Pretax Margin-101434.16%
Net Profit Margin-101601.85%
EBITDA Margin-101434.16%
EBIT Margin-101434.16%
Analyst Forecast
The average price target for BrightPath Biotherapeutics Co.Ltd. is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast1473.61%
EPS Growth Forecast22.61%